Lynparza shows promise in preventing cancer recurrence
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting
Read Moreby Selina McKee | Jun 4, 2021 | News | 0
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting
Read Moreby Anna Smith | Mar 18, 2019 | News | 0
A study has found that molecular patterns could better predict breast cancer recurrence.
Read Moreby Selina McKee | Aug 17, 2018 | News | 0
NICE is sticking with its position that Roche’s Perjeta is not cost-effective enough to be used by the NHS post surgery to prevent breast cancer recurrence.
Read Moreby Selina McKee | Jun 5, 2018 | News | 0
Bristol-Myers Squibb’s Opdivo, which is being investigated as adjuvant treatment after surgery for stage IIIb/c or IV melanoma patients at high risk of recurrence, may significantly cut the risk of patients’ cancer returning.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
